Jefferies upgraded Sumitomo Pharma to Buy from Hold with a price target of 1,050 yen, up from 830 yen ahead of a new medium-term plan scheduled to be released on April 28. The firm expects Sumitomo to turn profitable next year and "sustain growth for the foreseeable future," the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DNPUF: